The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study

The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study

Background Rituximab (RTX) is considered the first-line treatment for pemphigus vulgaris (PV), which is a B-cell-mediated acquired autoimmune disease. However, no consensus on the optimum dosage has been achieved.Objectives To investigate the efficacy and safety of low-dose RTX (a single infusion of...

Full description

Saved in:
Bibliographic Details
Main Authors: Xingli Zhou, Tongying Zhan, Xiaoxi Xu, Tianjiao Lan, Hongxiang Hu, Yuxi Zhou, Dengmei Xia, Jinqiu Wang, Yiyi Wang, Yue Xiao, Wei Li
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Journal of Dermatological Treatment
Subjects:
Pemphigus vulgaris
low-dose
rituximab
corticosteroids
adverse events
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2024.2302071
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items